


PHARMACEUTICAL 2018



Altimmune Inc. Rank 243 of 349







PHARMACEUTICAL 2018



Altimmune Inc. Rank 243 of 349

The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 343% points. The greatest weakness of Altimmune Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 239% points.

The company's Economic Capital Ratio, given in the ranking table, is -333%, being 55% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	23,466
Cost of Goods Sold	0
Intangible Assets	38,722
Liabilities, Current	3,840
Liabilities, Non-Current	0
Other Assets	239
Other Compr. Net Income	2,998
Other Expenses	30,281
Other Liabilities	10,513
Other Net Income	-19
Property and Equipment	603
Research and Development	18,406
Revenues	10,738
Selling, General and Administrative Expense	8,458

Output Variable	Value in 1000 USD
Assets	63,030
Liabilities	14,353
Expenses	57,145
Stockholders Equity	48,678
Net Income	-46,425
Comprehensive Net Income	-44,926
Economic Capital Ratio	-333%

